Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Serum ferritin has been suggested as a tumor marker in the diagnosis of certain malignancies and for following the activity or dissemination of the malignant process. Since neoplastic tissues generally contain more acidic isoferritins than their normal tissue counterparts, it has also been suggested that the specific assay of such isoferritins in serum may be of particular value in the diagnosis of malignancy. In this work, we have evaluated ferritin concentration in the serum of normal subjects and patients with acute nonlymphocytic leukemia, Hodgkin's disease, breast cancer and lung cancer by simultaneously using three different immunoassays: an immunoradiometric assay based on polyclonal antibodies against human liver (basic, L-subunit rich) ferritin, a radioimmunoassay based on polyclonad antibodies against HeLa cell (acidic, H-subunit rich) ferritin, and an immunoradiometric assay based on the monoclonal antibody 2A4 raised against human heart (acidic, H-subunit rich) ferritin. Most of the patients studied had increased values for liver-type ferritin in the absence of increased iron stores. Binding of serum ferritin to concanavalin A did not prove to be useful in distinguishing a tumor-specific basic isoferritin. The HeLa ferritin assay was found to be less specific than the heart ferritin assay in the detection of acidic isoferritins, and did not provide any advantage over the liver assay in detecting the increased levels of serum ferritin associated with malignant disease. Heart-type ferritin was found in one-fifth of normal sera and 64% of sera from patients with malignancy. Values were very low compared with those for basic ferritin, ranging from less than 0.1 to 17% of total serum ferritin (geometric mean value 1.3%) in patients with malignancy. These findings indicate that at present there is little application for serum ferritin immunoassays based on antibodies to HeLa cell or heart ferritin in the diagnosis or monitoring of malignant disease. This seems to be due to the presence in human serum of biding factors which are responsible for the rapid clearance of acidic isoferritins from the circulation. The serum concentration of basic ferritin, however, can be useful in the diagnosis and management of some malignancies, and it is possible that studies on cell isoferritins can be important in biologic monitoring of neoplastic disorders. It should also be noted that the increased levels of serum ferritin found in patients with malignancy can exert adverse effects on the host immune response and perhaps an inhibitory effect on hematopoiesis.
 ...
PMID:Immunological reactivity of serum ferritin in patients with malignancy. 408 87

The haemoglobin, serum iron, transferrin saturation, serum ferritin, erythrocyte sedimentation rate (ESR), splenic weight and non-haem iron concentration in the marrow, liver and spleen were measured prior to treatment in 35 patients with Hodgkin's disease who underwent staging laparatomy. The Hb, serum iron and transferrin saturation showed a significant decrease with increasing stage of the disease. In contrast, there was a significant increase in the serum ferritin, ESR, splenic weight and in all the tissue non-haem iron concentrations. The calculated total iron content of the body remained relatively constant throughout at about 2 g but with increasing stage there was an internal redistribution of iron, with a progressive drop in Hb iron and a reciprocal rise in storage iron, especially in the liver. Serum ferritin concentrations, which rose with progression of the disease, were inappropriately high in relation to the size of body stores at all stages but especially in patients with 4B disease and hepatic involvement. It was concluded that the serum ferritin concentrations are raised for several reasons in Hodgkin's disease. They reflect an increase in body iron stores, ferritin's role as an 'acute phase' protein in the inflammatory response and hepatic damage in patients with advanced disease.
 ...
PMID:Serum ferritin and Hodgkin's disease. 408 30

The spectre of methods for the diagnostics and differentiation of haemolytic anaemias, particularly for the establishment of congenital, autoimmune haemolytic, drug-conditioned and other anaemias is treated. The clear delimitation of an iron deficiency from a disturbance of the iron distribution is advantageously to be achieved by iron staining of the bone marrow and by a determination of serum ferritin. The value of the diagnostic methods in megaloblastic anaemia is classified according to newer knowledge, in which case the vitamin-B12-absorption test and the serum level determination of vitamin B12 by no means range in the first place. Long-term culture results of haematopoietic stem cells are particularly evident in the aplastic syndrome of the bone marrow and further haematological diseases concerning the establishment of the intensiveness of proliferation. The classification of the acute leukemias demands conventional as well as cytochemical staining methods; recently, it is essentially improved using monoclonal antibodies. In leukemias cytogenetic investigations are more and more attracted to the estimation of the prognoses. In lymphogranulomatosis among others functional disturbances of the cellular immunity, in the group of the non-Hodgkin-lymphomas haematological, protein-analytic and immunological laboratory investigations are methods supporting the diagnosis. Altogether is to be established that the haematological diagnostics has become more and more perfect, in which case apart from new techniques old approved methods are still further used.
 ...
PMID:[Rational hematologic diagnosis with reference to modern laboratory procedures]. 409 May 58

Antigens which exist in high frequency in tumor tissues of patients with Hodgkin's disease have been obtained in relatively concentrated form by gel chromatography procedures. Further purification and analysis of these antigens performed in the present study have demonstrated that the antigen of fast electrophoretic mobility (F-antigen) is normal tissue ferritin. The identification of F-antigen as ferritin has been made on the basis of comparative physicochemical and immunological analyses of purified F-antigen and normal ferritin. Thus, F-antigen was found to contain iron and to be similar to ferritin in molecular weight, amino-acid composition, electrophoretic mobility, isoelectric distribution, and immunological reactivity. Absorption of a monospecific heterologous anti-F antiserum with normal tissue ferritin completely removed all anti-F antibody activity. Moreover, the absorption of polyspecific heterologous antiserum to crude Hodgkin's extracts, which contains antibodies reacting with F-antigen, the slower migrating S-antigen, and a third specificity present in lysates of normal peripheral blood lymphocytes (PL-antigen), with ferritin, removed only anti-F activity, thus distinguishing the S- and PL-antigens from ferritin. The existence of ferritin in high quantities in serum of Hodgkin's disease patients may provide a tool of potential diagnostic and prognostic importance in the management of this disease.
 ...
PMID:Ferritin, a Hodgkin's disease associated antigen. 413 6

The serum ferritin concentration is increased in both acute myeloblastic leukaemia and Hodgkin's disease. In acute leukaemia the mean concentration is about ten times the normal level and is associated with a high concentration of transferrin-bound iron. In Hodgkin's disease abnormal ferritinaemia is associated with a low concentration of transferrin-bound iron and appears to result from a block of reticuloendothelial iron release. Increased concentrations of circulating ferritin have also been observed in a few cases of chronic leukaemia and myelomatosis.
 ...
PMID:Ferritinaemia in leukaemia and Hodgkin's disease. 451 89

An evaluation of iron metabolism has been carried out in 23 untreated patients with Hodgkin's disease and 6 patients with other lymphomata. The reduction in red cell life span is related to the stage of the disease. There is an almost universal impairment of iron release from the reticuloendothelial system with a consequent sideropenia and failure of iron delivery to the bone marrow for erythropoiesis. This defect is found in all stages of the disease and is not related to systemic symptoms.
 ...
PMID:Iron metabolism in Hodgkin's disease. 456 82

One hundred and forty three patients with lymphoreticular blastoma were examined 97 of them with Hodgkin disease in various clinical stages, 26 patients with reticulosarcoma and 20--with lymphosarcoma. The following indices were determined in all patients; hemoglobin, serum iron, total ironbinding capacity and the degree of saturation of transferins. Low values of serum iron were found in the exacerbated stages of patients with Hodgkin, especially in III and IV clinical stage. They are decreased also in patients with reticulosarcoma but to a less degree, while in those with lymphosarcoma--they are within normal limits. The total iron binding capacity is elevated in the same stages, the saturation degree of transferins being decreased. Hemoglobin increases in the stage of clinical improvement in the patients with Hodgkin, as well as iron and saturation degree of transferins. The total iron binding capacity is decreasedmthe changes in the above indices, though not specific, were concluded to be able to serve as additional tests in the determination of the period and to a certain extent, of the stage in patients with Hodgkin as well as to make a differential diagnosis with the rest lymphoreticular blastomas.
 ...
PMID:[A comparative study of iron and total iron binding capacity in the serum of patients with lymphoreticular blastomas]. 461 15

107 determinations of alpha 1-acid-glycoprotein (alpha 1S), haptoglobin (Hp) and complement fraction 3 (C3) were made in 85 consecutive patients with Hodgkin's disease, both in acute phase (77 measurements) and in complete remission (30 measurements). Only alpha 1S and Hp showed much higher levels in untreated disease than in remission, and elevation of alpha 1S in activity of the disease is correlated to advanced stages and - less significantly - to severe histology. The ability of alpha 1S, Hp and C3 to discriminate between activity and remission was compared with that of erythrocyte sedimentation rate (ESR), alpha 2-globinaemia (alpha 2), fibrinogenaemia (Fb), plasma copper (Cu) and iron (Fe), all data being collected at the same point in time in each patient. The well-known discrimination ability of combined Cu and Fe (75%) can be further improved by alpha 1S (81%) much more than by Hp, C3, ESR, alpha 2 and Fb singly computed and nearly up to the maximum allowed by the eight indexes together (82%).
 ...
PMID:Serum alpha-1-acid-glycoprotein, haptoglobin and C3 in Hodgkin's disease. A comparison with other acute-phase indicators. 618 May 85

The distribution of transferrin receptors (TR) has been studied in a range of normal and malignant tissues using four monoclonal antibodies, BK19.9, B3/25, T56/14 and T58/1. In normal tissues TR was found in a limited number of sites, notably basal epidermis, the endocrine pancreas, hepatocytes, Kupffer cells, testis and pituitary. This restricted pattern of distribution may be relevant to the characteristic pattern of iron deposition in primary haemachromatosis. In contrast to this limited pattern of expression in normal tissue, the receptor was widely distributed in carcinomas, sarcomas and in samples from cases of Hodgkin's disease. This malignancy-associated expression of the receptor may play a role in the anaemia of advanced malignancy by competing with the bone marrow for serum iron.
 ...
PMID:Transferrin receptors in human tissues: their distribution and possible clinical relevance. 630 35

Ferritins, a group of isomeric proteins that have important functions in iron metabolism and storage, have been demonstrated to be carcinoembryonic antigens. It has been recently shown that a subpopulation of lymphocytes from the peripheral blood of patients with Hodgkin's disease or breast cancer bear ferritin on their surface membranes. In view of the potential diagnostic and prognostic value of ascertaining the number of ferritin-bearing lymphocytes, the authors developed a simple indirect immunofluorescent technique for identifying them and used this technique to examine the peripheral blood lymphocytes of 44 patients with carcinomas of the head and neck (26), colon (14), and lung (4). It was found that patients with cancer had a mean percentage of 10% ferritin-bearing lymphocytes in their peripheral blood as compared with 3.1% in controls. Ferritin binding did not appear to be influenced by a cell's capacity to form sheep erythrocyte (E) rosettes since no correlation could be found between the percentages of lymphocytes bearing ferritin and those forming three different varieties of E-rosettes. There appeared to be no correlation of the percentages of ferritin-bearing lymphocytes with clinical staging except for a small, but significant (P less than 0.05), increase in the number of patients with head and neck cancer and nodal metastases. Although the functional significance of ferritin-bearing lymphocytes is currently unknown, the appearance of this subpopulation of cells in the blood appears to be associated with cancer. This assay may prove to be useful as a diagnostic tool, as a prognostic tool, or as a means of identifying patients at a risk for developing cancer and, therefore, it deserves further exploration.
 ...
PMID:Ferritin-bearing lymphocytes in patients with cancer. 636 Mar 36


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>